MSU
AZN icon

Maple Securities USA’s AstraZeneca AZN Stock Holding History

Maple Securities USA’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-10,935
Closed -$748K – 239
2015
Q1 		$748K Buy
+10,935
New +$760K 0.06% 73

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
MAA
Managed Account Advisors Jersey City, New Jersey $121B AUM 7.32% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return
CI
Cambiar Investors Denver, Colorado $2.3B AUM 24.77% 1-Year Est. Return
SCCM
Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return

Maple Securities USA's AZN Position: Q2 2015 in Review

Maple Securities USA sold out of AstraZeneca (AZN) in Q2 2015, closing a stake of 10,935 shares — an estimated $748K sold.

Maple Securities USA first reported a position in AZN in Q1 2015 and held it in 1 quarter. The position peaked at $748K in Q1 2015. 376 funds tracked by Wall St. Rank hold AZN as of Q2 2015.

  • Maple Securities USA reported no remaining AstraZeneca position as of Q2 2015 after selling out during the quarter.
  • Maple Securities USA sold 10,935 AstraZeneca shares in Q2 2015, an estimated $748K.
  • Maple Securities USA first reported a position in AstraZeneca in Q1 2015 and held it in 1 quarter.
  • Maple Securities USA's AstraZeneca position peaked at $748K in Q1 2015.
  • 376 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2015.

Based on Maple Securities USA's 13F filing for Q2 2015, filed 24 Jul 2015.